Franklin, Tenn.-based Acadia Healthcare will participate in a clinical trial for intranasal ketamine.
The randomized, double-blind, placebo-controlled study is intended to evaluate the effectiveness of the drug for treating suicidal ideation and major depression, Acadia said Sept. 14. Select Acadia hospitals will be included.
Patients who exhibit specific symptoms will be eligible for enrollment in the study, Acadia said.
Americans’ self-reported mental health has reached its lowest level in 24 years, with younger adults — especially women — experiencing…
Almost 500 mental health provider jobs have been eliminated in Colorado since the beginning of 2025, The Colorado Sun reported…
Penn Medicine’s Lancaster (Pa.) General Hospital opened a crisis walk-in center that provides immediate behavioral health assessments and treatments. The…
